Mitoxantrone

Generic Name: Mitoxantrone

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₈N_₄O_₆

CAS Number: 65271-80-9

Unique Ingredient Identifier: BZ114NVM5P

Background: An anthracenedione-derived antineoplastic agent.

Indication: For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Hodgkin's Lymphoma, Metastatic Breast Cancer, Non-Hodgkin's Lymphoma (NHL), Progressive Relapsing Multiple Sclerosis, Relapsed Leukemia, Relapsed Lymphomas, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Hormone refractory, advanced Prostate cancer, Relapsed Hepatocellular carcinoma

Associated Therapies: Autologous hematopoietic stem cell transplant

Clinical Trials

Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Biological: Lintuzumab-Ac-225
Drug: Cladribine
Drug: Cytarabine
Drug: Mitoxantrone
Drug: G-CSF

First Posted Date: 2018-02-22

Last Posted Date: 2024-10-07

Lead Sponsor: Medical College of Wisconsin

Target Recruit Count: 26

Registration Number: NCT03441048

Locations: 🇺🇸
Froedtert Hospital and the Medical College of Wisconsin, Milwuakee, Wisconsin, United States

Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Phase 3

Recruiting

Conditions: Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations

Interventions: Drug: Crenolanib
Drug: Cytarabine
Drug: Placebo Oral Tablet
Drug: Mitoxantrone
Drug: Fludarabine
Drug: Idarubicin
Drug: G-CSF

First Posted Date: 2017-08-15

Last Posted Date: 2021-04-30

Lead Sponsor: Arog Pharmaceuticals, Inc.

Target Recruit Count: 322

Registration Number: NCT03250338

Locations: 🇺🇸
Kansas University, Kansas City, Kansas, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇨🇦
University of Alberta, Edmonton, Alberta, Canada

and more 59 locations

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 2

Active, not recruiting

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndromes

Interventions: Drug: Azacitidine
Drug: Decitabine
Drug: Cytarabine
Drug: Daunorubicin
Drug: Etoposide
Combination Product: ITMHA
Drug: Idarubicin
Drug: Fludarabine
Drug: Mitoxantrone
Drug: Erwinia asparaginase
Drug: Sorafenib
Drug: G-CSF
Drug: Dexrazoxane
Drug: Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn
Biological: Stem Cell Transplant

First Posted Date: 2017-05-23

Last Posted Date: 2024-05-29

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 206

Registration Number: NCT03164057

Locations: 🇺🇸
Rady Children's Hospital and Health Center, San Diego, California, United States
🇺🇸
Children's Hospital of Central California, Madera, California, United States
🇺🇸
Children's Hospital of Orange County, Orange, California, United States

and more 7 locations

Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia

Phase 2

Completed

Conditions: AML

Interventions: Drug: Etoposide
Drug: Cytarabine
Drug: Lenalidomide
Drug: Mitoxantrone

First Posted Date: 2017-04-18

Last Posted Date: 2024-04-23

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 41

Registration Number: NCT03118466

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts general Hospital, Boston, Massachusetts, United States

National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple Sclerosis

Phase 3

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Interferon beta 1a
Drug: Mitoxantrone

First Posted Date: 2016-10-18

Last Posted Date: 2023-03-29

Lead Sponsor: Rennes University Hospital

Target Recruit Count: 35

Registration Number: NCT02937285

Locations: 🇫🇷
CHU Rennes, Rennes, France

Optimal Treatment Strategy Based on for Pediatric AML

Phase 2

Conditions: Pediatric Acute Myeloid Leukemia

Interventions: Drug: Cytarabine
Drug: Idarubicin
Drug: Mitoxantrone
Drug: Etoposide
Procedure: Hematopoietic stem cell transplantation

First Posted Date: 2016-07-28

Last Posted Date: 2016-07-28

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 350

Registration Number: NCT02848183

Locations: 🇰🇷
Chonnam National University Hwasun Hospital, Chonnam, Korea, Republic of
🇰🇷
St. Mary Hospital, Seoul, Korea, Republic of
🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 1

Completed

Conditions: Myelodysplastic Syndrome
Myeloproliferative Neoplasm
Acute Myeloid Leukemia
de Novo Myelodysplastic Syndrome
Acute Biphenotypic Leukemia

Interventions: Drug: Cladribine
Drug: Cytarabine
Biological: Filgrastim
Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Drug: Mitoxantrone
Drug: Sorafenib

First Posted Date: 2016-04-05

Last Posted Date: 2023-07-05

Lead Sponsor: University of Washington

Target Recruit Count: 84

Registration Number: NCT02728050

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia

Phase 3

Recruiting

Conditions: Acute Myeloid Leukaemia

Interventions: Drug: Mitoxantrone
Drug: Liposomal daunorubicin
Drug: Gemtuzumab ozogamicin
Drug: Fludarabine
Drug: Cytarabine
Drug: Busulfan
Drug: Cyclophosphamide

First Posted Date: 2016-03-31

Last Posted Date: 2021-10-08

Lead Sponsor: University of Birmingham

Target Recruit Count: 700

Registration Number: NCT02724163

Locations: 🇦🇺
Monash Children's Hospital, Melbourne, Australia
🇦🇺
Women and Children's Hospital Adelaide, Adelaide, Australia
🇦🇺
Queensland Children's Hospital, Brisbane, Australia

and more 65 locations

Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia

Phase 3

Active, not recruiting

Conditions: Acute Promyelocytic Leukemia

Interventions: Drug: Arsenic trioxide
Drug: Idarubicin
Drug: Cytarabine
Drug: Tretinoin
Drug: Mitoxantrone
Drug: Mercaptopurine
Drug: Methotrexate

First Posted Date: 2016-02-23

Last Posted Date: 2023-11-02

Lead Sponsor: Technische Universität Dresden

Target Recruit Count: 280

Registration Number: NCT02688140

Locations: 🇩🇪
OSHO study group, Multiple Locations, Germany
🇩🇪
SAL study group, Multiple Locations, Germany
🇳🇱
HOVON study group, Multiple Locations, Netherlands

and more 5 locations

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

Phase 1

Active, not recruiting

Conditions: Newly Diagnosed Acute Myeloid Leukemia (AML)
AML Arising After Exposure to Genotoxic Injury
Untreated AML
AML Arising From Myelodysplastic Syndrome (MDS)
AML Arising From Antecedent Hematologic Disorder (AHD)

Interventions: Drug: AG-120
Drug: AG-221
Drug: cytarabine
Drug: idarubicin
Drug: daunorubicin
Drug: mitoxantrone
Drug: etoposide

First Posted Date: 2015-12-17

Last Posted Date: 2024-07-25

Lead Sponsor: Institut de Recherches Internationales Servier

Target Recruit Count: 153

Registration Number: NCT02632708

Locations: 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

and more 14 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy